glp 1 agonists in development Market Overview: GLP-1 and the Obesity Market | Blog GLP-1 Agonists Market Report 2025-2033,

Sequence: Y-Aib-E-G-T-F-T-S-D-Y-S-I-Aib-L-D-K-I-A-Q-Aib-A-F-V-Q-W-L-I-A-G-G-P-S-S-G-A-P-P-P-S-NH2

Grading of Recommendations Assessment, Development and Evaluation (GRADE) showed moderate certainty for MACE, all-cause death and hospitalization for HF

Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from gut enteroendocrine cells that modulates glucose metabolism by controlling insulin excretion and glucagon secretion and inhibits gastric emptying leading to decreased food intake, thus limiting weight gain

Both drugs caused similar reductions in appetite, although tirzepatide caused greater weight loss

They are known to: - Lower blood sugar without causing hypoglycemia